The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 981-989

  Qin, C ^a   Cao, Q ^a   Ju, X ^a   Wang, M ^b   Meng, X ^a   Zhu, J ^a   Yan, F ^b   Li, P ^a   Ding, Q ^a   Chen, J ^a   Gu, M ^a   Zhang, W ^a   Yin, C ^a   Zhang, Z ^b  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

HIF1A; Polymorphism; Prognosis; Renal cell carcinoma; VHL

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOXIA INDUCIBLE FACTOR 1ALPHA GENE; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU GENE;

EID: 84859486689     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr325     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol 2006; 176: 2353-2358.
3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
4. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005; 31: 536-545.
5. Kawai Y, Sakano S, Korenaga Y et al. Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 2007; 52: 1147-1155.
6. Hirata H, Hinoda Y, Nakajima K et al. The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. J Urol 2009; 182: 721-727.
7. Hirata H, Hinoda Y, Kikuno N et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007; 13: 4123-4129.
8. Kleinrath T, Gassner C, Lackner P et al. Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. J Clin Oncol 2007; 25: 845-851.
9. Lin J, Horikawa Y, Tamboli P et al. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010; 31: 1805-1812.
10. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
11. Baldewijns MM, van Vlodrop IJ, Vermeulen PB et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol 2010; 221: 125-138.
12. Clifford SC, Astuti D, Hooper L et al. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 2001; 20: 5067-5074.
13. Chau CH, Permenter MG, Steinberg SM et al. Polymorphism in the hypoxiainducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005; 4: 1222-1225.
14. Tanimoto K, Yoshiga K, Eguchi H et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 2003; 24: 1779-1783.
15. Zhao T, Lv J, Zhao J, Nzekebaloudou M. Hypoxia-inducible factor-1alpha gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res 2009; 28: 159.
16. Lee JY, Choi JY, Lee KM et al. Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women. Clin Chim Acta 2008; 389: 167-170.
17. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet 2004; 153: 122-126.
18. Nadaoka J, Horikawa Y, Saito M et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer 2008; 122: 1297-1302.
19. Munoz-Guerra MF, Fernandez-Contreras ME, Moreno AL et al. Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol 2009; 16: 2351-2358.
20. Fransen K, Fenech M, Fredrikson M et al. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Mol Carcinog 2006; 45: 833-840.
21. Zhu J, Qin C, Wang M et al. Functional polymorphisms in cell death pathway genes and risk of renal cell carcinoma. Mol Carcinog 2010; 49: 810-817.
22. Yamada N, Horikawa Y, Oda N et al. Genetic variation in the hypoxia-inducible factor-1alpha gene is associated with type 2 diabetes in Japanese. J Clin Endocrinol Metab 2005; 90: 5841-5847.
23. Nagy G, Kovacs-Nagy R, Kereszturi E et al. Association of hypoxia inducible factor-1 alpha gene polymorphism with both type 1 and type 2 diabetes in a Caucasian (Hungarian) sample. BMC Med Genet 2009; 10: 79.
24. Hsiao PC, Chen MK, Su SC et al. Hypoxia inducible factor-1alpha gene polymorphism G1790A and its interaction with tobacco and alcohol consumptions increase susceptibility to hepatocellular carcinoma. J Surg Oncol 2010; 102: 163-169.
25. Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 2007; 67: 8-13.
26. Birner P, Schindl M, Obermair A et al. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-4696.
27. Batmunkh E, Shimada M, Morine Y. Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma.. Int J Clin Oncol 2010; 15: 59-64.
28. Lidgren A, Hedberg Y, Grankvist K et al. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol 2006; 50: 1272-1277.
29. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000; 20: 1527-1533.
30. Kohler HH, Barth PJ, Siebel A et al. Quantitative assessment of vascular surface density in renal cell carcinomas. Br J Urol 1996; 77: 650-654.
31. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997; 80: 401-404.
32. Sandlund J, Hedberg Y, Bergh A et al. Endoglin (CD105) expression in human renal cell carcinoma. BJU Int 2006; 97: 706-710.
33. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163: 343-347.
34. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-811.
35. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of posttranscriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-114.
36. Brauch H, Weirich G, Brieger J et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60: 1942-1948.
37. Schraml P, Struckmann K, Hatz F et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002; 196: 186-193.
38. Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94: 1569-1575.
39. Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep 2009; 11: 94-101.
40. Gossage L, Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat Rev Clin Oncol 2010; 7: 277-288.